Processing

Please wait...

PATENTSCOPE will be unavailable a few hours for maintenance reason on Tuesday 25.01.2022 at 8:00 PM JST
Settings

Settings

Goto Application

Offices all Languages Stemming false Single Family Member true Include NPL false

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:C07

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.20220008477METHODS AND COMBINATIONS FOR TREATMENT AND T CELL MODULATION
US 13.01.2022
Int.Class A61K 35/28
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
28Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
Appl.No 17292363 Applicant Juno Therapeutics, Inc. Inventor Jens HASSKARL

The present disclosure relates in some aspects to methods, compositions and uses involving immunotherapies, such as adoptive cell therapy, e.g., T cell therapy, and an immunomodulatory compound, such as a structural or functional analog or derivative of thalidomide and/or an inhibitor of E3-ubiquitin ligase. The provided methods, compositions and uses include those for combination therapies involving the administration or use of one or more immunomodulatory compounds in conjunction with a T cell therapy, such as a genetically engineered T cell therapy involving cells engineered with a recombinant receptor, such as chimeric antigen receptor (CAR)-expressing T cells. Also provided are compositions, methods of administration to subjects, articles of manufacture and kits for use in the methods. In some aspects, features of the methods and cells provide for increased or improved activity, efficacy, persistence, expansion and/or proliferation of T cells for adoptive cell therapy or endogenous T cells recruited by immunotherapeutic agents.

2.20220009994COMPOSITIONS FOR INCREASING HALF-LIFE OF A THERAPEUTIC AGENT IN FELINES AND METHODS OF USE
US 13.01.2022
Int.Class C07K 14/705
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
705Receptors; Cell surface antigens; Cell surface determinants
Appl.No 17355839 Applicant Invetx Inc. Inventor William Brondyk

Provided are compositions for increasing the half-life of a polypeptide or polypeptides in a feline and methods of their use. The compositions involve variant feline IgG Fc regions.

3.WO/2022/007461IMMUNOMODULATOR
WO 13.01.2022
Int.Class C07D 409/12
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
409Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
02containing two hetero rings
12linked by a chain containing hetero atoms as chain links
Appl.No PCT/CN2021/087548 Applicant HITGEN INC. Inventor LI, Jin
Disclosed is an immunomodulator, and the present invention specifically relates to a compound for inhibiting IL-17A and an application of the compound serving as the immunomodulator in the preparation of a drug. Disclosed is an application of a compound represented by formula I or a stereoisomer thereof in preparing a drug for inhibiting IL-17A, and a new choice for clinically screening and/or preparing a drug for treating diseases related to IL-17A activity is provided.
4.WO/2022/007866FUSED TRICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL APPLICATION THEREOF
WO 13.01.2022
Int.Class C07D 233/76
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
233Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
54having two double bonds between ring members or between ring members and non-ring members
66with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
72Two oxygen atoms, e.g. hydantoin
76with substituted hydrocarbon radicals attached to the third ring carbon atom
Appl.No PCT/CN2021/105088 Applicant SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. Inventor WU, Junjun
A fused tricyclic derivative relating to the technical field of chemical drugs, a preparation method therefor, and a pharmaceutical application thereof. The fused tricyclic derivative is an inhibitor of aggrecanase-2 (ADAMTS-5). Also provided are a pharmaceutical composition comprising the compound and a use of the compound in the preparation of a drug for treating diseases such as osteoarthritis.
5.WO/2022/0079863'3' CYCLIC DINUCLEOTIDES WITH AN ALKENYLENE
WO 13.01.2022
Int.Class C07H 21/02
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
21Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
02with ribosyl as saccharide radical
Appl.No PCT/CZ2021/050043 Applicant INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY AS CR, V. V. I. Inventor BIRKUS, Gabriel
The present disclosure relates to 3'3' cyclic phosphonate dinucleotides of general formula (J), their pharmaceutically acceptable salts, their pharmaceutical composition and combinations of said substances and other medicaments or pharmaceuticals. The disclosure also relates to the use of said compounds for the treatment or prevention of diseases or conditions modifiable by STING protein modulation, such as cancer or viral, allergic and inflammatory diseases. In addition, these substances can be used as adjuvants in vaccines. (Formula (J))
6.WO/2022/008451A SOLID POLYMER COMPOSITION, A SELF-SUPPORTING FILM AND A LIGHT EMITTING DEVICE
WO 13.01.2022
Int.Class C09K 11/02
CCHEMISTRY; METALLURGY
09DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
KMATERIALS FOR APPLICATIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
11Luminescent, e.g. electroluminescent, chemiluminescent, materials
02Use of particular materials as binders, particle coatings or suspension media therefor
Appl.No PCT/EP2021/068523 Applicant AVANTAMA AG Inventor LÜCHINGER, Norman, Albert
The invention refers in a first aspect to self-supporting film comprising green luminescent crystals (1), red luminescent crystals (2), and a polymer (3). The green luminescent crystals (1) are perovskite crystals. The red luminescent crystals (2) are zincblende or wurzite, preferably zincblende, crystals. A second aspect of the invention refers to a solid polymer composition (100). A third aspect of the invention refers to a light emitting device comprising either the solid polymer composition (100) or the self-supporting film.
7.WO/2022/008646ANTIBODIES THAT BIND PSMA AND GAMMA-DELTA T CELL RECEPTORS
WO 13.01.2022
Int.Class C07K 16/28
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
Appl.No PCT/EP2021/068960 Applicant LAVA THERAPEUTICS N.V. Inventor ROOVERS, Robertus Cornelis
The present invention relates to antibodies capable of binding human PSMA and capable of binding a human Vγ9Vδ2 T cell receptor. The invention further relates to pharmaceutical compositions comprising the antibodies of the invention and to uses of the antibodies of the invention for medical treatment.
8.WO/2022/008856METHOD FOR PREPARATION OF A HEPTANOIC ACID TRIGLYCERIDE
WO 13.01.2022
Int.Class C07C 67/08
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
CACYCLIC OR CARBOCYCLIC COMPOUNDS
67Preparation of carboxylic acid esters
08by reacting carboxylic acids or symmetrical anhydrides with the hydroxy or O-metal group of organic compounds
Appl.No PCT/FR2021/051284 Applicant ARKEMA FRANCE Inventor LEBRUN, Stéphanie
The invention relates to a method for preparation of a triglyceride, comprising a step of bringing glycerin into contact with heptanoic acid, the heptanoic acid being in excess relative to the glycerin and the method being carried out in the absence of catalysts. The invention also relates to a triglyceride obtained from the method as well as the use of said triglyceride as a nutritional supplement in animal and/or human food.
9.WO/2022/008946OPTICALLY PURE ENANTIOMERS OF RUTHENIUM COMPLEXES AND USES THEREOF
WO 13.01.2022
Int.Class C07F 15/00
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
FACYCLIC, CARBOCYCLIC, OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
15Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic System
Appl.No PCT/IB2020/000920 Applicant CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE Inventor JAZZAR, Rodolphe
The present invention relates to an optically pure (+) or (–) enantiomer of a ruthenium complex having the following formula (I) as well as the preparation method of said enantiomer, and uses thereof as catalyst, in particular in asymmetric olefin metathesis.
10.WO/2022/008976USE OF GDF11 TO DIAGNOSE AND TREAT ANXIETY AND DEPRESSION
WO 13.01.2022
Int.Class G01N 33/68
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
68involving proteins, peptides or amino acids
Appl.No PCT/IB2021/000495 Applicant INSTITUT PASTEUR Inventor KATSIMPARDI, Lida
Provided are methods for the detection of GDF11 in a subject having or suspected of having a mood and/or anxiety disorder, comprising providing a sample from a subject having or suspected of having a mood and/or anxiety disorder; contacting the sample with a GDF11-binding molecule; and detecting bound GDF11. Also provided are methods of diagnosing or characterizing a mood and/or anxiety disorder in a subject, comprising providing a sample from a subject; contacting the sample with a GDF11-binding molecule; detecting bound GDF11; and comparing the levels of detected bound GDF11 to healthy reference levels. Also provided are methods of treating or preventing a mood and/or anxiety disorder and/or accelerated aging in a subject in need thereof, comprising administering to the subject an agent or composition which increases the levels of GDF11 polypeptide in the subject.